Comparison · NCT02607124-63f9a56f
RB+ High Grade Glioma vs Non-Biopsied Diffuse Instrinsic Pontine Glioma: Number of Patients Alive at One Year
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. RB+ High Grade Glioma vs Non-Biopsied Diffuse Instrinsic Pontine Glioma: Number of Patients Alive at One Year. Trial comparisons, record NCT02607124-63f9a56f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02607124-63f9a56f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.793 | wilson | |
| Risk in group 2 | 0.889 | 0.565 | 0.98 | wilson | |
| Risk difference, group 1 minus group 2 | -0.889 | -0.98 | -0.0319 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with the outcome on RB+ High Grade Glioma than on Non-Biopsied Diffuse Instrinsic Pontine Glioma | 1.13 | 1.02 | 31.4 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | RB+ High Grade Glioma | Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (\>21 yrs of age 600mg daily (DIPG); \<21 yrs of age 350 mg/m2/day)~Ribociclib | 0 | 1 | OG000 |
| Group 2 | Non-Biopsied Diffuse Instrinsic Pontine Glioma | Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (\>21 yrs of age 600mg daily (DIPG); \<21 yrs of age 350 mg/m2/day)~Ribociclib | 8 | 9 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Patients Alive at One Year
- Description
- Time frame
- 1 year
- Population
- Number of enrolled and evaluable participants
Source ClinicalTrials.gov
Trial
- Title
- A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy
- NCT number
- NCT02607124
- Phases
- PHASE1, PHASE2
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Bithalamic High Grade Glioma
- Interventions
- Ribociclib
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Results first posted
- 2020-11-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02607124?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02607124-63f9a56f